Drug Patents owned by Biomarin Pharm
1. Drug name - KUVAN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612073 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
Nov, 2024
(2 years from now) | |
| US9433624 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| USRE43797 | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
Nov, 2024
(2 years from now) | |
| US7566714 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| US8067416 | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
Nov, 2024
(2 years from now) | |
| US7727987 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(2 years from now) | |
| US8318745 | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
Nov, 2024
(2 years from now) | |
|
USRE43797
(Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin |
May, 2025
(2 years from now) | |
|
US7612073
(Pediatric) | BIOMARIN PHARM | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
May, 2025
(2 years from now) | |
|
US8067416
(Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(2 years from now) | |
|
US7566714
(Pediatric) | BIOMARIN PHARM | Methods and compositions for the treatment of metabolic disorders |
May, 2025
(2 years from now) | |
|
US7727987
(Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(2 years from now) | |
|
US8318745
(Pediatric) | BIOMARIN PHARM | Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
May, 2025
(2 years from now) | |
| US7566462 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(3 years from now) | |
| US8003126 | BIOMARIN PHARM | Stable tablet formulation |
Nov, 2025
(3 years from now) | |
|
US7566462
(Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(3 years from now) | |
|
US8003126
(Pediatric) | BIOMARIN PHARM | Stable tablet formulation |
May, 2026
(3 years from now) | |
| US9216178 | BIOMARIN PHARM | Dry blend formulation of tetrahydrobiopterin |
Nov, 2032
(10 years from now) | |
Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient
Treatment: To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption; Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; Kuvan is indicated to reduce blood phenylalanine levels in patients with hyperphenylalaninemia
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 100MG | TABLET;ORAL | Prescription |
2. Drug name - VOXZOGO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8198242 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
Jun, 2030
(7 years from now) | |
| CN102481330B | BIOMARIN PHARM | C-Type Natriuretic Peptide Variants |
May, 2030
(7 years from now) | |
| CN102481330A | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| IN391651B | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| IN201109124P1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP3175863A1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP3175863B1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489A4 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489A2 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| EP2432489B1 | BIOMARIN PHARM | Variants Of C-Type Natriuretic Peptide |
May, 2030
(7 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE48267 | BIOMARIN PHARM | Variants of C-type natriuretic peptide |
May, 2030
(7 years from now) | |
| US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
| US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
Drugs and Companies using VOSORITIDE ingredient
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 0.4MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 0.56MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
| 1.2MG/VIAL | POWDER;SUBCUTANEOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.